Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMG592Q)

• Drug Name: Solifenacin Drug Info
• Synonyms: Vesicare; Vesikur; Solifenacin succinate; Solifenacin succinate [USAN]; YM 905; Solifenacin (INN); Solifenacin [INN:BAN]; Vesicare (TN); YM-53705; YM-67905; YM-905; Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylatemonosuccinate; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; Butanedioic acid, compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); Butanedioic acid, cmpd. with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); 1-azabicyclo[2.2.2]oct-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo(2.2.2)oct-3-yl ester, (1S)-, butanedioate (1:1)
• Therapeutic Class: Antispasmodics
• Cross-matching ID:
  PubChem CID: 154059
  ChEBI ID: CHEMBL1734
  CAS Number: CAS 242478-37-1
  TTD Drug ID: D0L4YD
  INTEDE Drug ID: DR1497

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
ECM-receptor interaction	2.10	0.00e+0	80/88 (90.91%)	COL6A3;COL6A2;VWF;...
Biosynthesis of unsaturated fatty acids	2.06	0.00e+0	21/27 (77.78%)	SCD;SCD5;ACOT7;...
Steroid biosynthesis	2.03	0.00e+0	19/20 (95%)	DHCR24;MSMO1;SQLE;...
Histidine metabolism	1.83	4.21e-2	16/22 (72.73%)	AOC1;MAOA;CNDP2;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	3H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼